Addenbrooke's Charitable Trust Logo
Close
Menu

Author: Paul White

Exciting Progress on the New Cambridge Children’s Hospital!

Posted on by Paul White

We are thrilled to share some fantastic news about the progress of the Cambridge Children’s Hospital project. Our journey to create a groundbreaking new hospital that will revolutionise the way we care for children and young people has reached a significant milestone.

A Major Step Forward

We are delighted to announce that Bouygues UK has been appointed as the construction partner for the new Cambridge Children’s Hospital. This partnership marks a major step forward in our mission to build a hospital that unites mental and physical healthcare with world-leading life sciences research. Our goal is to treat the mind and body as one – treating the Whole Child – their health and well-being, individual educational needs, and their family.

Matt Allen, Director of New Hospital Construction at Cambridge University Hospitals, said: “We are delighted to be working with Bouygues UK. This is a major milestone in the journey to deliver Cambridge Children’s Hospital. Bouygues UK is a first-class contractor with proven expertise in building and delivering excellent healthcare infrastructure within a collaborative environment. This makes them an ideal construction partner to deliver such an important project.”

Bouygues Construction has delivered over 400 healthcare facilities globally, including the major new cancer and surgery centre for the University College London Hospital (UCLH) Grafton Way Building, a complex 13-storey facility with a state-of-the-art proton beam therapy centre. The firm are currently leading the build of Oriel, the joint initiative between Moorfields Eye Hospital NHS Foundation Trust, the UCL Institute of Ophthalmology and Moorfields Eye Charity to build a new integrated centre for advancing eye health in Camden and the new Ambulatory Diagnostic Centre at West Middlesex University Hospital. They recently delivered the University of Cambridge’s Cavendish Laboratory known as the Ray Dolby Centre, pioneering the future of scientific research and innovation.

A Unique Approach to Care

The new hospital will be the first specialist children’s hospital for the East of England, the only region in the UK without one. It will bring together clinical excellence from two NHS Trusts and pioneering research from the University of Cambridge. Located at the heart of the Cambridge Biomedical Campus, Europe’s largest biomedical campus, the hospital will provide a holistic approach to care, focusing on the health and well-being of the whole child, their educational needs, and their family.

Community Involvement

Children, young people, parents, and carers have been and will continue to be at the forefront of shaping how Cambridge Children’s Hospital will look, feel, and care. The Youth Forum and Young Adult Forum have been instrumental in contributing ideas around the design of the hospital, based on their own lived experiences of attending hospital and using mental health services.

Katie Birditt, Chair of the Cambridge Children’s Hospital Youth and Young Adult Forums, shared her excitement: “I have been involved in the design journey for a while now and it’s amazing to see this hospital finally becoming reality. Knowing that there will be a place built just for children and young people—where mental and physical health are treated together—fills me with hope. I’m really proud to be part of something that’s going to help so many families in the future”.

Innovative Design and Facilities

Spread over six floors, the hospital will include 108 inpatient beds, 16 paediatric intensive care beds, 42 day-case beds, seven operating theatres, imaging and diagnostics, and a hospital school. A world-leading 5000 sqm research institute will be embedded within the hospital, bringing University of Cambridge researchers and NHS clinicians together to create a collaborative and multi-disciplinary environment dedicated to improving the health of children and young people.

Looking Ahead

Professor Isobel Heyman, Clinical Co-Lead for Mental Health for Cambridge Children’s Hospital, said: “This truly is an exciting moment for the project. We are bringing specialist care closer to home so children and families across the East of England will have better, more equitable access to the care they need – with less time away from school, home, and community.”

With the appointment of Bouygues UK, the project can move into its next phase with renewed confidence and excitement. We anticipate that construction will start within the next 18 months, and we are excited to see this vision come to life.

This pioneering new children’s hospital will only be possible through public fundraising, which is being carried out in partnership between Addenbrooke’s Charitable Trust, the University of Cambridge, and Head to Toe Charity, who are fundraising to secure additional significant donations needed to make this hospital possible. Thanks to the public’s generosity and support the fundraising campaign has already passed the halfway mark, but so much more is needed yet. If you would like to be a part of making this pioneering new hospital a reality then you can find out more about getting involved by clicking here.

Thank you for your continued support as we work towards building a brighter future for children and young people in the East of England. Together, we are making history!

Stay tuned for more updates on the Cambridge Children’s Hospital project.

New Treatment Approach Shows Promise for Aggressive Breast Cancers 

Posted on by Paul White

A ground-breaking trial, funded with the help of ACT supporters, has led to a significant improvement in survival rates for patients with aggressive, inherited breast cancers. Cambridge researchers have discovered that a new treatment approach, involving chemotherapy followed by a targeted cancer drug before surgery, has resulted in a 100% survival rates for patients who took part in a trial three years post-surgery.

Published today in the journal Nature Communications, this discovery could become the most effective treatment to date for early-stage breast cancer patients with inherited BRCA1 and BRCA2 gene mutations. These types of breast cancers are notoriously difficult to treat, gaining public attention when actress Angelina Jolie, a BRCA1 carrier, underwent a preventative double mastectomy in 2013.

The current standard treatment aims to shrink the tumour using chemotherapy and immunotherapy before removing the tumour through surgery. However, the first three years after surgery are critical, with the highest risk of relapse after death. The Partner trial took a different approach, demonstrating two key innovations: the addition of olaparib and chemotherapy pre-surgery, and the benefits of careful timing of treatments. Olaparib, a targeted cancer drug taken as tablets, is already available on the NHS.

Led by Addenbrooke’s Hospital, part of Cambridge University Hospitals (CUH) NHS Foundation Trust and the University of Cambridge, the trial recruited patients from 23 NHS sites across the UK. Results show that leaving a 48-hour gap between chemotherapy and olaparib leads to better outcomes, possibly because the patient’s bone marrow has time to recover from chemotherapy while leaving the tumour cells susceptible to the targeted drug. Of the 39 patients who received chemotherapy followed by olaparib only one relapsed three years after surgery, and 100% survived. In comparison, the survival rate for the control arm was 88% three years after surgery.

Jackie Van Bochoven, a 59-year-old from South Cambridgeshire, was diagnosed in February 2019 with a small but aggressive tumour. She shared her experience: “When I had the diagnosis, I was completely shocked and numb. I thought about my children, and my mum and sister who were diagnosed with breast cancer. I was pretty worried. Six years on, I’m well and cancer-free. I’m back at work, enjoying life and spending time with my family. When you’ve had cancer, I think you look at life differently and every day is a bonus”.

Patient Jackie Van Bochoven (second left) and her daughters – Danielle, Charlotte and Jocelyn (L to R)
Copyright: Cambridge University Hospitals

The findings have the potential to be applied to other cancers caused by faulty copies of the BRCA genes, such as some ovarian, prostate, and pancreatic cancers. It may also have cost-saving benefits for the NHS, as patients currently offered olaparib take the drug post-surgery for 12 months, whereas patients on the trial took the tablets pre-surgery for 12 weeks.

Professor Jean Abraham, Addenbrooke’s Hospital.
Copyright: Stillvision photography

Professor Jean Abraham, Addenbrooke’s consultant and trial lead, expressed excitement about the potential of this new approach: “It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer. We’re incredibly excited about the potential of this new approach, as its crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers”.

Shelly Thake, CEO of Addenbrooke’s Charitable Trust, which supported the Partner trial with funding from our kind supporters, said: “One of the greatest privileges we have as a charity is supporting transformative, pioneering and radical people. The finest minds in their fields whose research is shaping the future of healthcare, doing things differently so that we can stop people suffering from cancers we should be beating. Jean is one of those individuals, and her work developing personalised breast cancer treatments remains one of the most powerful examples of what ACT – and the wonderful people who donate to ACT – can make possible. This news gives hope to countless women who live with the fear of aggressive, inherited breast cancers. It is also a profound example of what the new Cambridge Cancer Research Hospital that we are currently fundraising for will make possible, and why there is nowhere else other than Cambridge where this hospital would be possible with its critical mass of clinicians, researchers, world-class hospitals and pioneering organisations such as the University and pharmaceutical companies”.

ACT supported Professor Abraham by funding her salary for two years, which enabled her to work on multiple breast cancer projects.

“That kind of support at that stage is a boost in that it gives you the feeling that someone believes in what you are doing. It is always good to get someone else to verify that your ideas are sound, and if people back it with money then that’s a very big statement of support. So, from my perspective, having ACT’s funding to support me was a very visible and real sign of the belief in my abilities and there’s no price you can put on that kind of confidence at that stage in your career.”

“Probably the most undervalued quality in science and medicine is determination and persistence because this wasn’t straight forward. We went to more than one drug company to get a drug; we didn’t always get the funding that we should have got and there have been a lot of hurdles.

We had to get through COVID – there’s been a lot that has happened. Some of the firms that were doing the work of testing went bust. A lot happens when you are trying to deliver a trial, so for anyone who is more junior and is thinking of a career as a clinical trialist or clinical academic, I would say, obviously you have to be smart and have general ideas, but fundamentally you have to be determined, persistent and not let other people’s inability to see what you see stop you. To have that belief in yourself and your team and to take the project forward I think is really important.”

Mark O’Connor, chief scientist in Early Oncology R&D at AstraZeneca, added: “The Partner trial highlights the importance of detecting and treating cancer early, and the value of innovative science in informing clinical trial design. While the findings need to be validated in a larger study, they’re incredibly exciting and have the potential to transform outcomes for patient populations who have unmet clinical needs”.

This collaboration between NHS, academia, and industry, reflects the vision of the Cambridge Cancer Research Hospital, a specialist cancer research hospital due to be built on Europe’s leading life sciences campus, the Cambridge Biomedical Campus. It will bring clinical expertise from Addenbrooke’s Hospital together with world-class scientists from the University of Cambridge, Cancer Research UK Cambridge Centre, and industry partners to create new diagnostics and treatments to detect the earliest signs of cancer and deliver personalised, precision medicine.

Michelle Mitchell, Chief Executive of Cancer Research UK, commented: “One of the best ways that we can beat cancer sooner is by making more effective use of treatments that are already available to us. While this research is still in its infancy, it is an exciting discovery that adding olaparib at a carefully-timed stage of treatment can potentially give patients with this specific type of breast cancer more time with their loved ones. Research like this can help find safer and kinder ways to treat certain types of cancer. Further studies in more patients are needed to confirm whether this new technique is safe and effective enough to be used by the NHS”.

Professor Abraham and the team are now planning the next phase of the research, which will look to replicate the results in a larger study and confirm that the Partner approach offers a less toxic treatment for patients as well as being more cost-effective to the current standard of care. She said:

“All jobs have their moments. The privilege I have is that you are always grounded by your patients because no matter how tough you think you are having it, you know that your patients are having it a great deal tougher. And actually, the thing that should motivate you is not whether you can get an H paper or an H Comms paper (a metric used to measure the productivity and impact of a researcher’s publications), both of which we got, but actually it’s ‘will it make a difference to the people that you see every week in clinic?’ that should be your driver.”

The Partner trial was sponsored by Cambridge University Hospitals (CUH) NHS Foundation Trust and the University of Cambridge, funded by Cancer Research UK and AstraZeneca, and supported by Addenbrooke’s Charitable Trust (ACT), the NIHR Cambridge Biomedical Research Centre, and the Cancer Research UK Cambridge Centre.